China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China
· Delayed Price · Currency is CNY 18.55
-0.25 (-1.33%)
Feb 28, 2025, 2:44 PM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 2.62B CNY in the quarter ending September 30, 2024, with 0.55% growth. This brings the company's revenue in the last twelve months to 10.32B, down -5.44% year-over-year. In the year 2023, China Resources Double-Crane Pharmaceutical had annual revenue of 10.22B with 6.20% growth.
Revenue (ttm)
10.32B
Revenue Growth
-5.44%
P/S Ratio
1.84
Revenue / Employee
841.30K
Employees
12,269
Market Cap
19.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10.22B | 596.82M | 6.20% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | 8.50B | -877.05M | -9.35% |
| Dec 31, 2019 | 9.38B | 1.16B | 14.05% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Mindray Bio-Medical Electronics | 37.11B |
| Jiangsu Hengrui Medicine | 26.00B |
| WuXi AppTec | 38.50B |
| Aier Eye Hospital Group | 20.62B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
| Shanghai United Imaging Healthcare | 10.93B |
| Yunnan Baiyao Group Co.,Ltd | 39.34B |
| Sichuan Biokin Pharmaceutical | 5.85B |